Company Overview of Octapharma AG
Octapharma AG develops, produces, and sells human proteins that are derived from human plasma and human cell-lines. The company develops and manufactures haematology products, including coagulation factor concentrates for patients with bleeding disorders; and immunotherapy products comprising human immunoglobulin products for treating various immune-mediated diseases and deficiencies. It also offers critical care products, such as human plasma and protein products for treating critically ill or injured patients in intensive care and emergency settings. The company provides its products under the albuminativ, albunorm, atenativ, aunativ, gammanorm, nanofix, nanotiv, octafix, octagam, octagam ...
Founded in 1983
Key Executives for Octapharma AG
Chairman of Management Board
Chief Financial Officer and Member of Management Board
Member of Management Board and President of Octapharma Plasma Inc Usa
Member of Management Board and President for Octapharma Usa Inc
Senior Vice President of R&D Plasma - Vienna
Compensation as of Fiscal Year 2014.
Octapharma AG Key Developments
Octapharma AG Reports Earnings Results for the Year Ended December 31, 2013
Mar 4 14
Octapharma AG reported earnings results for the year ended December 31, 2013. For the year, the company reported net profit of EUR 124.40 million, compared to EUR 135.75 million for the year ended December 31, 2012. Net sales were EUR 1.15 billion, compared to EUR 915.65 million for the year ended December 31, 2012. Operating income was EUR 149.92 million, compared to EUR 136.78 million for the year ended December 31, 2012.
Octapharma AG Enters into Agreement with Pfizer Inc. for the Future Commercialization and Marketing in the U.S. of Human Prothrombin Complex Concentrate
Dec 11 13
Octapharma AG announced that it has entered into an agreement with Pfizer Inc. for the future marketing and commercialization of human prothrombin complex concentrate (PCC), an investigational agent currently under FDA review for the urgent reversal of Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients who require urgent surgery or invasive procedures. Under the terms of the agreement, Octapharma AG has exclusive rights to commercialize this product globally, with the exception of the U.S. where Pfizer will exclusively be responsible for marketing and commercialization. The BLA for the product was submitted by Octapharma AG in April 2013 and is currently under FDA review. Octapharma AG's PCC is approved for use in 75 countries outside the U.S. under the brand name Octaplex(R) and was first approved for use in Germany in 2003 (it is branded as Ocplex(R) in Sweden and Pronativ(R) in Australia).
Octapharma AG Signs Supply Agreement with Ethicon
Oct 25 13
Octapharma AG has signed a long-term, strategic supply agreement with Ethicon. Under the agreement, supply of the biological components will begin after all necessary process validations are completed and regulatory approvals have been achieved.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|